Compare Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Global ex-US Real Estate Index Fd ETF vs Zoetis Inc — how do they compare? Vanguard Global ex-US Real Estate Index Fd ETF trades at $42.16 (market cap $3.80B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 7.9× Vanguard Global ex-US Real Estate Index Fd ETF's market cap, and Zoetis Inc pays a 2.9% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days and Zoetis Inc for 70 Days on average.
| VNQI | ZTS | |
|---|---|---|
Market Cap | $3.80B | $30.20B |
Volume | 277,049 | 6,175,327 |
52-Week High | $50.76 | $147.53 |
52-Week Low | $41.81 | $69.09 |
Typical Hold Time | 95 Days | 70 Days |
Sector | — | Health |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $42.08, up 0.63% with bearish technical signals from moving averages. The ETF provides international real estate exposure across 30+ countries, offering a higher dividend yield than domestic alternatives. Recent news highlights a significant 45.9% drop in short interest in September 2026, while technical indicators show oversold conditions with RSI readings below 30.
The ETF faces headwinds from global real estate market volatility but offers diversification benefits and income potential. Key risks include international currency exposure and regional economic uncertainties. The substantial decline in short interest suggests potential sentiment improvement, though technical trends remain bearish near-term.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
